| Emerging evidence points towards metabolic inflammation as a key process in metabolic-dysfunction associated steatotic liver disease (MASLD). MASLD is characterized by multiorgan morbidity and key extrahepatic comorbidities that are influenced by MASLD are type 2 diabetes, cardiovascular disease and neurocognitive function. Importantly, the presence of metabolic-dysfunction associated steatohepatitis (MASH) and advanced liver fibrosis increase the risk for systemic comorbidity in MASLD. Although the precise nature of the crosstalk between the liver and other organs has not yet been fully elucidated, there is emerging evidence that metabolic inflammation - in part emanating from the fatty liver - is the engine that drives cellular dysfunction, cell death and deleterious remodelling within various body tissues. The presentation will provide clinical evidence and describe inflammatory pathways that have been implicated as links between MASLD disease progression and extrahepatic disease. |
